

Eric Assenat

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6682166/publications.pdf>

Version: 2024-02-01

72
papers

14,935
citations

136950

32
h-index

74163

75
g-index

79
all docs

79
docs citations

79
times ranked

17391
citing authors

#	ARTICLE	IF	CITATIONS
1	FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer. <i>New England Journal of Medicine</i> , 2011, 364, 1817-1825.	27.0	6,140
2	FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer. <i>New England Journal of Medicine</i> , 2018, 379, 2395-2406.	27.0	1,931
3	Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α -fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2019, 20, 282-296.	10.7	1,202
4	Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial. <i>Lancet Oncology</i> , The, 2017, 18, 1624-1636.	10.7	595
5	Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial. <i>Lancet Oncology</i> , The, 2022, 23, 77-90.	10.7	526
6	Effect of Everolimus on Survival in Advanced Hepatocellular Carcinoma After Failure of Sorafenib. <i>JAMA - Journal of the American Medical Association</i> , 2014, 312, 57.	7.4	515
7	2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. <i>Lancet Oncology</i> , The, 2019, 20, e566-e581.	10.7	458
8	Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO): a randomised, open-label, non-comparative phase 2 trial. <i>Lancet Oncology</i> , The, 2014, 15, 819-828.	10.7	345
9	Establishment and Characterization of a Cell Line from Human Circulating Colon Cancer Cells. <i>Cancer Research</i> , 2015, 75, 892-901.	0.9	321
10	Personalised versus standard dosimetry approach of selective internal radiation therapy in patients with locally advanced hepatocellular carcinoma (DOSISPHERE-01): a randomised, multicentre, open-label phase 2 trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2021, 6, 17-29.	8.1	307
11	Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study. <i>Lancet Oncology</i> , The, 2018, 19, 682-693.	10.7	285
12	Objective response by mRECIST as a predictor and potential surrogate end-point of overall survival in advanced HCC. <i>Journal of Hepatology</i> , 2017, 66, 1166-1172.	3.7	178
13	Interleukin 1 γ inhibits CAR-induced expression of hepatic genes involved in drug and bilirubin clearance. <i>Hepatology</i> , 2004, 40, 951-960.	7.3	146
14	Intravoxel Incoherent Motion-derived Histogram Metrics for Assessment of Response after Combined Chemotherapy and Radiation Therapy in Rectal Cancer: Initial Experience and Comparison between Single-Section and Volumetric Analyses. <i>Radiology</i> , 2016, 280, 446-454.	7.3	136
15	KRAS G12D Mutation Subtype Is A Prognostic Factor for Advanced Pancreatic Adenocarcinoma. <i>Clinical and Translational Gastroenterology</i> , 2016, 7, e157.	2.5	135
16	Lean body mass as an independent determinant of dose-limiting toxicity and neuropathy in patients with colon cancer treated with FOLFOX regimens. <i>Cancer Medicine</i> , 2016, 5, 607-616.	2.8	119
17	Excessive alcohol consumption after liver transplantation impacts on long-term survival, whatever the primary indication. <i>Journal of Hepatology</i> , 2012, 57, 306-312.	3.7	118
18	Nutritional support during oncologic treatment of patients with gastrointestinal cancer: Who could benefit?. <i>Cancer Treatment Reviews</i> , 2008, 34, 568-575.	7.7	106

#	ARTICLE	IF	CITATIONS
19	MR Volumetric Measurement of Low Rectal Cancer Helps Predict Tumor Response and Outcome after Combined Chemotherapy and Radiation Therapy. <i>Radiology</i> , 2012, 263, 409-418.	7.3	95
20	A Randomized Phase II Trial of Three Intensified Chemotherapy Regimens in First-Line Treatment of Colorectal Cancer Patients with Initially Unresectable or Not Optimally Resectable Liver Metastases. The METHEP Trial. <i>Annals of Surgical Oncology</i> , 2013, 20, 4289-4297.	1.5	80
21	Cetuximab Plus FOLFIRINOX (ERBIRINOX) as First-Line Treatment for Unresectable Metastatic Colorectal Cancer: A Phase II Trial. <i>Oncologist</i> , 2011, 16, 1557-1564.	3.7	74
22	Molecular Portrait of Metastasis-Competent Circulating Tumor Cells in Colon Cancer Reveals the Crucial Role of Genes Regulating Energy Metabolism and DNA Repair. <i>Clinical Chemistry</i> , 2017, 63, 700-713.	3.2	67
23	Pathophysiological Factors Affecting CAR Gene Expression. <i>Drug Metabolism Reviews</i> , 2003, 35, 255-268.	3.6	63
24	Dual targeting of HER1/EGFR and HER2 with cetuximab and trastuzumab in patients with metastatic pancreatic cancer after gemcitabine failure: results of the "THERAPY" phase 1-2 trial. <i>Oncotarget</i> , 2015, 6, 12796-12808.	1.8	56
25	Prophylactic Percutaneous Endoscopic Gastrostomy in Patients With Advanced Head and Neck Tumors Treated by Combined Chemoradiotherapy. <i>Journal of Pain and Symptom Management</i> , 2011, 42, 548-556.	1.2	53
26	Sorafenib Overcomes Irinotecan Resistance in Colorectal Cancer by Inhibiting the ABCG2 Drug-Efflux Pump. <i>Molecular Cancer Therapeutics</i> , 2013, 12, 2121-2134.	4.1	48
27	Incidence of solid organ cancers after liver transplantation: comparison with regional cancer incidence rates and risk factors. <i>Liver International</i> , 2015, 35, 1748-1755.	3.9	47
28	Sorafenib alone vs. sorafenib plus GEMOX as 1st-line treatment for advanced HCC: the phase II randomised PRODIGE 10 trial. <i>British Journal of Cancer</i> , 2019, 120, 896-902.	6.4	42
29	NOD1 Participates in the Innate Immune Response Triggered by Hepatitis C Virus Polymerase. <i>Journal of Virology</i> , 2016, 90, 6022-6035.	3.4	39
30	Serum alpha-fetoprotein and clinical outcomes in patients with advanced hepatocellular carcinoma treated with ramucirumab. <i>British Journal of Cancer</i> , 2021, 124, 1388-1397.	6.4	39
31	Differential regulation of constitutive androstane receptor expression by hepatocyte nuclear factor4 β isoforms. <i>Hepatology</i> , 2007, 45, 1146-1153.	7.3	35
32	KRAS genotyping in rectal adenocarcinoma specimens with low tumor cellularity after neoadjuvant treatment. <i>Modern Pathology</i> , 2012, 25, 731-739.	5.5	33
33	Targeting the Wnt Pathway and Cancer Stem Cells with Anti-progastrin Humanized Antibodies as a Potential Treatment for K-RAS-Mutated Colorectal Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 5267-5280.	7.0	32
34	Immunonutrition before and during radiochemotherapy: improvement of inflammatory parameters in head and neck cancer patients. <i>Supportive Care in Cancer</i> , 2012, 20, 3129-3135.	2.2	31
35	Idarubicin-loaded Beads for Chemoembolization of Hepatocellular Carcinoma: The IDASPHERE II Single-Arm Phase II Trial. <i>Radiology</i> , 2019, 291, 801-808.	7.3	31
36	Effect of ramucirumab on ALBI grade in patients with advanced HCC: Results from REACH and REACH-2. <i>JHEP Reports</i> , 2021, 3, 100215.	4.9	31

#	ARTICLE	IF	CITATIONS
37	Ramucirumab in elderly patients with hepatocellular carcinoma and elevated alpha-fetoprotein after sorafenib in REACH and REACH-2. <i>Liver International</i> , 2020, 40, 2008-2020.	3.9	26
38	Phase 1b/2 trial of tepotinib in sorafenib pretreated advanced hepatocellular carcinoma with MET overexpression. <i>British Journal of Cancer</i> , 2021, 125, 190-199.	6.4	26
39	Bone metastases in gastrointestinal cancer. <i>Clinical and Experimental Metastasis</i> , 2015, 32, 7-14.	3.3	24
40	Hepatitis C viral proteins perturb metabolic liver zonation. <i>Journal of Hepatology</i> , 2015, 62, 278-285.	3.7	23
41	Phase III study evaluating the association of gemcitabine, trastuzumab and erlotinib as first-line treatment in patients with metastatic pancreatic adenocarcinoma (GATE 1). <i>International Journal of Cancer</i> , 2021, 148, 682-691.	5.1	23
42	The p53 isoform delta133p53 Δ regulates cancer cell apoptosis in a RhoB-dependent manner. <i>PLoS ONE</i> , 2017, 12, e0172125.	2.5	23
43	Quantification of HER Expression and Dimerization in Patients' Tumor Samples Using Time-Resolved Förster Resonance Energy Transfer. <i>PLoS ONE</i> , 2012, 7, e37065.	2.5	21
44	SBRT planning for liver metastases: A focus on immobilization, motion management and planning imaging techniques. <i>Reports of Practical Oncology and Radiotherapy</i> , 2017, 22, 103-110.	0.6	21
45	Percutaneous thermal ablation of hepatocellular carcinomas located in the hepatic dome using artificial carbon dioxide pneumothorax: retrospective evaluation of safety and efficacy. <i>International Journal of Hyperthermia</i> , 2018, 35, 90-96.	2.5	21
46	Association of COVID-19 Lockdown With the Tumor Burden in Patients With Newly Diagnosed Metastatic Colorectal Cancer. <i>JAMA Network Open</i> , 2021, 4, e2124483.	5.9	21
47	Machine Learning-Assisted Evaluation of Circulating DNA Quantitative Analysis for Cancer Screening. <i>Advanced Science</i> , 2020, 7, 2000486.	11.2	19
48	Small cell carcinoma with concomitant adenocarcinoma arising in a Barrett's oesophagus: report of a case with a favourable behaviour. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2008, 452, 103-107.	2.8	18
49	EGFR and HER3 mRNA expression levels predict distant metastases in locally advanced rectal cancer. <i>International Journal of Cancer</i> , 2011, 128, 2938-2946.	5.1	18
50	Evaluating bevacizumab in combination with FOLFIRI after the failure of platinum-etoposide regimen in patients with advanced poorly differentiated neuroendocrine carcinoma: The PRODIGE 41 BEVANEC randomized phase II study. <i>Digestive and Liver Disease</i> , 2018, 50, 195-198.	0.9	17
51	Second-line therapy for gemcitabine-pretreated advanced or metastatic pancreatic cancer. <i>World Journal of Gastroenterology</i> , 2012, 18, 1357.	3.3	17
52	Characterization of a novel PXR isoform with potential dominant-negative properties. <i>Journal of Hepatology</i> , 2014, 61, 609-616.	3.7	15
53	Regional Differences in Efficacy, Safety, and Biomarkers for Second-Line Axitinib in Patients with Advanced Hepatocellular Carcinoma: From a Randomized Phase II Study. <i>Liver Cancer</i> , 2018, 7, 148-164.	7.7	12
54	Is chronic hepatitis C virus infection a risk factor for breast cancer?. <i>World Journal of Gastroenterology</i> , 2010, 16, 3687.	3.3	12

#	ARTICLE	IF	CITATIONS
55	The oncogenic and druggable hPG80 (Progastrin) is overexpressed in multiple cancers and detected in the blood of patients. <i>EBioMedicine</i> , 2020, 51, 102574.	6.1	10
56	Validation of an appropriate reference gene for normalization of reverse transcriptionâ€“quantitative polymerase chain reaction data from rectal cancer biopsies. <i>Analytical Biochemistry</i> , 2009, 388, 348-350.	2.4	9
57	Identification of proteomic changes during human liver development by 2D-DIGE and mass spectrometry. <i>Journal of Hepatology</i> , 2009, 51, 114-126.	3.7	9
58	Interventional oncology for hepatocellular carcinoma. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2016, 40, 530-537.	1.5	9
59	Sequential first-line treatment with nab-paclitaxel/gemcitabine and FOLFIRINOX in metastatic pancreatic adenocarcinoma: GABRINOX phase Ib-II controlled clinical trial. <i>ESMO Open</i> , 2021, 6, 100318.	4.5	9
60	Small Steatotic HCC: A Radiological Variant Associated With Improved Outcome After Ablation. <i>Hepatology Communications</i> , 2021, 5, 689-700.	4.3	8
61	A phase III study evaluating oral glutamine and transforming growth factor-beta 2 on chemotherapy-induced toxicity in patients with digestive neoplasm. <i>Digestive and Liver Disease</i> , 2016, 48, 327-332.	0.9	7
62	Progression of AFP SCORE is a Preoperative Predictive Factor of Microvascular Invasion in Selected Patients Meeting Liver Transplantation Criteria for Hepatocellular Carcinoma. <i>Transplant International</i> , 2022, 35, 10412.	1.6	7
63	MR imaging of locally advanced low rectal cancer: Relationships between imaging findings and the pathological tumor regression grade. <i>Journal of Magnetic Resonance Imaging</i> , 2015, 42, 421-426.	3.4	6
64	Anticancer Drugs for Intra-Arterial Treatment of Colorectal Cancer Liver Metastases: In-Vitro Screening after Short Exposure Time. <i>Pharmaceuticals</i> , 2021, 14, 639.	3.8	6
65	Doxorubicin for the treatment of hepatocellular carcinoma: GAME OVER!. <i>Annals of Translational Medicine</i> , 2020, 8, 1693-1693.	1.7	6
66	Outcome after pancreatectomy for neuroendocrine neoplasms according to the WHO 2017 grading system: A retrospective multicentric analysis of 138 consecutive patients. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2020, 44, 286-294.	1.5	4
67	Cost-Utility Analysis of Transarterial Radioembolization With Yttrium-90 Resin Microspheres Compared With Sorafenib in Locally Advanced and Inoperable Hepatocellular Carcinoma. <i>Clinical Therapeutics</i> , 2021, 43, 1201-1212.	2.5	4
68	FOLFIRINOX for the treatment of colorectal cancer: latest evidence from clinical trials. <i>Colorectal Cancer</i> , 2012, 1, 181-184.	0.8	2
69	Quantitative evaluation of liver metastases density on computed tomography: A new tool to evaluate early response to bevacizumab-containing chemotherapy. <i>Digestive and Liver Disease</i> , 2019, 51, 1185-1191.	0.9	2
70	Initial endoscopic description of esophageal squamous cell carcinomas. <i>Gastroenterologie Clinique Et Biologique</i> , 2006, 30, 1365-1370.	0.9	1
71	Multimodal treatment including surgery for esophageal adenocarcinoma with liver oligo-metastases: a pathological complete response but early brain metastasis. <i>Clinical Journal of Gastroenterology</i> , 2020, 13, 713-716.	0.8	1
72	Reply to: â€œArginase 1: a potential marker of a common pattern of liver steatosis in HCV and NAFLD childrenâ€“. <i>Journal of Hepatology</i> , 2015, 62, 1208-1209.	3.7	0